Interestingly, we observed a favorable response to anti-PD1 plus TKI combination therapy in two ASPSCR1-TFE3 fusion tRCC patients in this study. The gene discussed is ASPSCR1; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.